Summary

Singapore’s fertility rate reached 0.87 in 2025, while the CPF MediSave lifetime lifetime withdrawal limit for assisted conception remains S$15,000 since 2004. This white paper recommends raising the lifetime withdrawal limit to S$25,000 while limiting MediSave-supported in vitro fertilisation to three complete cycles. Official Consumer Price Index data show that All Items prices rose 53.5% between 2004 and 2025 and Health prices rose 59.9%. Preserving the original lifetime withdrawal limit’s purchasing power therefore implies S$23,027 or S$23,988. A round S$25,000 limit is a defensible reset allowing uncertainty. The recommended schedule is S$10,000 for the first cycle, S$8,000 for the second, and S$7,000 for the third. Funding should stop thereafter because prognosis is heterogeneous with declining marginal returns for many patients, repeated treatment consumes protected medical savings, and an open-ended entitlement would weaken cost control. This proposed boundary is a financing rule, not a clinical prohibition: further treatment may proceed through private payment or exceptional budget-funded assistance. Elective egg freezing and routine preimplantation genetic testing for aneuploidy should remain excluded. Implementation requires prognosis review, personalised balance disclosure, outcome reporting, invoice controls, targeted equity support, and five-year evaluation of affordability, healthy singleton live birth, account depletion, and provider prices.

Keywords: assisted reproductive technology; CPF MediSave; health financing; in vitro fertilisation; medical inflation; Singapore

Executive Policy Position

Singapore should raise the lifetime CPF MediSave withdrawal lifetime withdrawal limit for clinically indicated in vitro fertilisation (IVF) and currently eligible assisted-conception procedures from S$15,000 to S$25,000, while retaining a firm boundary of three complete MediSave-supported IVF cycles. The increase should be understood as a periodic restoration of the real value of a lifetime withdrawal limit designed in 2004, not as open-ended reproductive financing.

The recommended schedule is up to S$10,000 for the first complete cycle, S$8,000 for the second, and S$7,000 for the third, exhausting the S$25,000 lifetime lifetime withdrawal limit. These amounts approximately translate the original S$6,000/S$5,000/S$4,000 schedule by healthcare inflation and round it into administratively simple limits. A complete cycle should include one ovarian-stimulation episode and all fresh and frozen embryo transfers arising from that retrieval, so that clinics and patients cannot multiply claims by relabelling transfer stages.

The proposed S$25,000 lifetime withdrawal limit is slightly above the strict 2025 inflation equivalents of approximately S$23,027 under the All Items CPI and S$23,988 under the Health CPI. That modest buffer is justified by uncertainty in mapping broad indices to IVF-specific charges, current public-provider fee ranges, and the desirability of a durable round-number limit. It is not evidence for automatic indexation or unlimited future increases.

MediSave financing should end after three complete cycles. This is a financing boundary rather than a clinical ban. Cumulative live-birth studies show that some patients can succeed after more attempts, but average figures conceal large differences by age, ovarian response, embryo development, diagnosis, and prior failure. A protected medical-savings scheme should support a defined, clinically meaningful course rather than every potentially beneficial intervention. Further lawful IVF may be privately financed, or considered under exceptional, transparent and budget-funded assistance where independent review finds unusually favourable prognosis and severe financial hardship.

The reform should preserve exclusions for elective egg freezing and routine preimplantation genetic testing for aneuploidy (PGT-A), retain clinically indicated PGT-M and PGT-SR, require prognosis review before the second and third cycles, provide personalised MediSave-balance disclosure, and establish national reporting of cumulative healthy singleton live birth, medical-savings depletion, equity, maternal-neonatal outcomes, and provider price responses.

1. Purpose, Scope and Decision Question

Singapore’s resident total fertility rate fell from 0.97 in 2024 to 0.87 in 2025, while resident live births declined by 11.1% to 27,393 [1]. These figures justify a whole-of-government response, but they do not establish that every fertility expenditure should be financed from MediSave. Low fertility reflects interacting constraints involving partnership formation, housing, work intensity, caregiving, delayed childbearing, desired family size, and biological infertility. ART addresses an important subset of these constraints; MediSave policy addresses only how that subset is financed.

This paper asks two linked questions. First, what lifetime withdrawal limit now preserves the practical value of the S$15,000 limit structured in 2004? Second, should a higher lifetime withdrawal limit finance more than three complete IVF cycles? The proposals are assessed against preservation of purchasing power, clinical effectiveness, affordability, distributive fairness, protection of later-life medical savings, and administrative governability.

The resulting position is deliberately differentiated. A S$25,000 lifetime withdrawal limit is justified as a contemporary reset because strict inflation adjustment produces values close to S$24,000 and current treatment charges are material. Funding beyond three complete cycles is not justified from protected medical savings because later success is heterogeneous, marginal benefit generally declines, opportunity costs rise, and a clear boundary disciplines both patient expectations and provider prices. The policy should update the monetary amount without expanding the treatment course or the technology set.

2. Existing Support and the Origin of the S$15,000 lifetime withdrawal limit

Singapore already provides substantial support for ART. At public assisted-reproduction centres, eligible couples may receive government co-funding of up to 75%, subject to citizenship and cycle caps. For a couple comprising two Singapore citizens, current per-cycle co-funding caps are S$7,700 for a fresh ART cycle, S$2,200 for a frozen cycle, and S$1,000 for intrauterine insemination. Co-funding is available for up to three fresh and three frozen ART cycles, with specified flexibility for some women aged 40 or older [2].

MediSave may supplement this assistance. The current withdrawal schedule permits S$6,000 for the first assisted-conception cycle, S$5,000 for the second, and S$4,000 for the third and subsequent cycles, subject to a S$15,000 lifetime limit per patient. Withdrawals may come from the patient’s or spouse’s account. MediSave may also be used within prevailing limits for clinically indicated preimplantation genetic testing for monogenic or single-gene defects (PGT-M) and structural chromosomal rearrangements (PGT-SR) [2].

The present monetary structure dates to 2004. In a 2006 policy reply, the Ministry of Health stated that MediSave use for assisted-conception procedures had been revised in 2004 to S$6,000, S$5,000 and S$4,000 for the first three treatment cycles respectively. The same historical record reported that one IVF cycle then ranged from S$7,000 to S$20,000 depending on provider and treatment [3]. The S$15,000 cumulative lifetime withdrawal limit was therefore a policy calibration to the conditions of that period, not a monetary constant designed to remain unchanged indefinitely.

The correct comparison is not between a S$15,000 lifetime withdrawal limit and no safeguard. It is between an unadjusted 2004 amount and a still-bounded contemporary lifetime withdrawal limit that funds the same three-cycle course. Retaining the former indefinitely allows inflation to rewrite policy silently; extending withdrawals beyond three cycles would alter the policy’s scope rather than merely restore its value.

3. Inflation Supports a S$25,000 Contemporary Reset

Calculations from the Singapore Department of Statistics’ official monthly CPI series show that the annual-average All Items index increased from 65.732 in 2004 to 100.903 in 2025, a cumulative rise of approximately 53.5%. The Health index increased from 64.192 to 102.653, a cumulative rise of approximately 59.9% [4]. On these benchmarks, preserving the 2004 purchasing power of S$15,000 would imply approximately S$23,027 under general inflation or S$23,988 under healthcare inflation.

A S$25,000 lifetime withdrawal limit is 66.7% above the existing nominal limit, approximately 8.6% above the All Items CPI equivalent and 4.2% above the Health CPI equivalent. That is a modest policy buffer, not a radical expansion. Broad price indices cannot capture every change in fertility medication, embryology, laboratory practice, storage, regulation, provider mix, or case complexity. Rounding the healthcare-inflation benchmark to S$25,000 reduces false precision and creates a durable, easily communicated lifetime withdrawal limit.

The CPI evidence must be interpreted carefully. The Health index measures a broad basket rather than IVF tariffs alone; it does not prove that every clinic fee rose by 59.9%. Its policy relevance is that a fixed medical-withdrawal lifetime withdrawal limit loses real capacity over two decades. Conversely, the small buffer above healthcare inflation should not become a precedent for automatic annual indexation. Government should reassess the lifetime withdrawal limit periodically using observed IVF charges, outcomes, account adequacy, and CPI evidence together.

4. Contemporary Treatment Charges Support a Bounded Reset

Current provider information illustrates the old cap’s diminished scale. Singapore General Hospital estimates IVF treatment at S$15,000–S$18,000 and lists the unchanged S$6,000/S$5,000/S$4,000 MediSave schedule [5]. In 2024, KK Women’s and Children’s Hospital estimated a fresh IVF cycle for a Singapore citizen at S$12,000–S$16,000, while a private provider reported charges from about S$15,000 to S$17,700 [6].

These figures are not directly comparable with the full 2004 range because case mix, medication, laboratory practice, provider type, and included services differ. They nevertheless show that the entire S$15,000 lifetime lifetime withdrawal limit can now be comparable to one contemporary treatment episode before co-funding and patient-specific variation. A lifetime withdrawal limit intended to assist a course of treatment should not become nominally static while the underlying bundle changes.

Existing co-funding substantially reduces out-of-pocket expense. The Ministry of Health reported that after co-funding and MediSave use for a first assisted-conception cycle, eight in ten eligible Singapore-citizen couples incurred no out-of-pocket payment and nine in ten paid no more than S$500 [7]. This argues against removing safeguards, but it does not answer the affordability of second and third attempts after initial failure.

The recommended S$10,000/S$8,000/S$7,000 schedule is transparent and evidence-led. Applying 59.9% healthcare inflation to the 2004 amounts produces approximately S$9,594, S$7,995 and S$6,396; the proposed values round these to administratively simple limits and allocate the small policy buffer principally to the third cycle. The schedule restores capacity across the same defined treatment course rather than financing additional cycles.

5. Rising CPF Contribution Settings Strengthen—but Do Not Decide—the Case

The CPF savings environment has also changed since 2004. The Ordinary Wage lifetime withdrawal limit was S$5,500 per month in January 2004 and is S$8,000 in 2026, a rise of approximately 45.5% [8]. For employees aged 55 and below earning more than S$750 per month, total CPF contributions in 2026 equal 37% of wages, comprising 17% from the employer and 20% from the employee, subject to applicable lifetime withdrawal limits [9].

Current allocation ratios imply MediSave contributions of approximately 8.0% of wages for members aged 35 and below, 9.0% for those above 35–45, 10.0% for those above 45–50, and 10.5% for those above 50–55 [10]. At the S$8,000 Ordinary Wage lifetime withdrawal limit, this corresponds to monthly MediSave inflows of approximately S$640, S$720, S$800 and S$840 respectively before Additional Wages.

These developments make a bounded nominal reset more administratively plausible, but they do not prove that every patient has S$25,000 available or that withdrawal is costless. Members differ by income, employment continuity, age, prior medical spending, caregiving responsibilities, and attainment of the Basic Healthcare Sum. Compulsory contributions remain protected savings rather than disposable income.

The proper inference is therefore limited: the lifetime withdrawal limit should not be assessed against a frozen 2004 savings environment, but contribution growth cannot replace an adequacy analysis. Implementation should monitor post-treatment balances and Basic Healthcare Sum attainment by income and age. Use should remain voluntary, and each patient should receive a personalised illustration of how the proposed withdrawal affects future medical savings.

6. MediSave Stewardship in a Super-Aged Society

In 2026, Singapore reached “super-aged” status, commonly defined as a population in which at least 21% are aged 65 or older. By 2030, one in four citizens is expected to be at least 65 [11]. Longer lives extend exposure to chronic disease, hospitalisation, rehabilitation, long-term care, and recurring outpatient costs. The fiscal horizon for MediSave policy is measured in decades.

A withdrawal is not costless merely because it comes from an individual account rather than a current appropriation. If fertility treatment depletes balances that would otherwise meet later medical needs, costs may reappear as family transfers, means-tested assistance, unpaid bills, or higher public spending. This temporal fiscal externality supports a lifetime lifetime withdrawal limit and a cycle boundary even when the lifetime withdrawal limit’s nominal value is updated.

The S$25,000 proposal is compatible with stewardship because it restores roughly the 2004 real value, confines withdrawals to three complete cycles, excludes elective services and weakly evidenced add-ons, and requires balance disclosure and outcome monitoring. The same reasoning does not support removing the lifetime withdrawal limit, funding fourth and later cycles automatically, or indexing the limit without an affirmative policy review.

Equity also requires distinguishing withdrawal permission from financial assistance. Higher-income households can more readily replenish savings or finance later cycles privately; lower-income patients may not possess S$25,000 to withdraw. A higher lifetime withdrawal limit can reduce cash-flow pressure for those with balances, but it cannot deliver equal access by itself. If cost prevents clinically appropriate treatment among lower-income patients, targeted grants financed from general revenue are the proper redistributive complement.

7. Repeated IVF: Why MediSave Funding Should Stop After Three Complete Cycles

Later IVF cycles are not uniformly futile. In a United Kingdom cohort of 156,947 women, the live-birth rate in the first cycle was 29.5%. Among women younger than 40 using their own oocytes, the first-cycle rate was 32.3% and the prognosis-adjusted cumulative live-birth rate after six cycles was 68.4%. Among women aged 40–42, the corresponding first-cycle rate was 12.3% and the adjusted cumulative rate after six cycles was 31.5%; for women older than 42, the live-birth rate remained below 4% in every cycle [12].

A population-based analysis of 113,873 women found that 29.1% achieved live birth after the first complete IVF cycle and 43.0% after up to six complete cycles. Age, duration of infertility, oocyte yield, embryo cryopreservation, and embryo developmental stage materially altered prognosis [13]. Earlier United States data reported six-cycle cumulative live-birth estimates of 51% under a conservative assumption and 72% under an optimistic assumption, but only 23% and 42% respectively among women aged 40 or older [14].

These studies establish that a fourth or later cycle can help selected patients; they do not establish an entitlement to finance every potentially beneficial cycle from MediSave. Cumulative percentages combine patients with very different prognoses and depend on assumptions about those who discontinue treatment. The relevant policy question is whether protected medical savings should support an open-ended sequence after a substantial three-cycle course, not whether the probability of success becomes literally zero.

Three complete cycles form a defensible boundary for five reasons. First, they provide repeated opportunities to adjust stimulation and learn from prior response. Second, early cycles generally capture the highest-prognosis treatment margin. Third, prognosis after repeated failure becomes increasingly dependent on individual factors that population averages cannot resolve. Fourth, a fixed boundary protects later-life savings and limits pressure for fee inflation. Fifth, it aligns with a recognised comparative public-policy benchmark: current NICE guidance recommends three full IVF cycles for eligible women under 40 and a more restrictive course for women aged 40–42, demonstrating that a three-cycle course can represent substantial public support rather than abandonment [15].

The boundary should be defined by complete cycles, encompassing one ovarian stimulation and all fresh and frozen embryo transfers generated by that retrieval. Prognosis review should occur before the second and third cycles and cover diagnosis, age, ovarian response, oocyte yield, fertilisation, embryo development, transfer history, comorbidity, and estimated live-birth probability. After the third complete cycle, no further MediSave withdrawal should be permitted. This is a financing rule, not an absolute clinical stop: lawful additional treatment may proceed through private payment. Exceptional public assistance, if offered, should be budget-funded, means-tested, independently reviewed, and transparently reported rather than hidden inside a general MediSave entitlement.

8. Clinical Volume Is Not Equivalent to Demographic Effectiveness

ART contributes meaningfully to births. Australian analysis estimated that ART accounted for approximately 4%–5% of the total fertility rate, roughly one in twenty births, with particular importance for first births at older maternal ages [16] It would be incorrect to dismiss ART as demographically irrelevant. The policy question is how many additional healthy births arise from restoring purchasing power within three cycles, and at what cost to medical savings.

Cross-national evidence does not show that financing expansion reliably produces a large population-level fertility effect. An interrupted time-series study of Korean national insurance coverage for ART found no significant change in marriage or pregnancy rates. It observed small increases in multiple pregnancy and multiple birth and a slowing in the decline of total births, but did not establish a clear level increase in total births attributable to coverage [17] Institutional differences prevent direct transfer to Singapore, but the study cautions against treating reimbursement as a demographic lever with predictable yield.

Countervailing economic evidence deserves weight. An Australian model concluded that at least five publicly funded IVF cycles could provide value for women younger than 42 under assumptions about willingness to pay for a child and future fiscal contributions [18]. This does not establish that compulsory personal medical savings are the best instrument or that the result transfers to Singapore. The model concerns a different system and depends on age, treatment cost, success, discounting, and the monetary value assigned to future births.

The S$25,000 lifetime withdrawal limit is therefore best justified as affordability and purchasing-power maintenance within a defined course, not as a claim that it will reverse national fertility decline. Government should measure the reform’s marginal effect on completion of the first three cycles, cumulative healthy singleton live birth, out-of-pocket spending, and account depletion rather than presume demographic returns.

9. Treatment Expansion Carries Downstream Health-System Costs

ART safety has improved, and many patients have uncomplicated pregnancies. Nevertheless, financing analysis should count downstream maternal and neonatal outcomes. A meta-analysis of 50 cohort studies, including 161,370 ART-conceived and 2,280,241 spontaneously conceived singleton pregnancies, found higher relative risks associated with ART for pregnancy-induced hypertension, gestational diabetes, placenta previa, placental abruption, preterm birth, low birth weight, perinatal mortality, and congenital malformation [19]. These observational associations should not be interpreted as wholly caused by ART because infertility and parental characteristics may confound them.

Professional guidance identifies multifetal gestation as the greatest preventable ART-associated risk and recommends limiting embryo transfer, promoting elective single-embryo transfer, and counselling patients before treatment. It also recognises that adverse outcomes may be more frequent even among ART singletons while causal attribution remains uncertain [20].

The policy response is not to deny IVF or retain an obsolete nominal lifetime withdrawal limit. It is to attach the additional withdrawal capacity to quality conditions. Participating centres should follow clinically appropriate single-embryo-transfer standards and report multiple births, maternal complications, neonatal outcomes, and cumulative healthy singleton live births. The reform should be judged by outcomes, not cycles initiated or pregnancies recorded.

10. Elective Egg Freezing Should Remain Outside MediSave

Planned oocyte cryopreservation can expand reproductive autonomy and may enable a later genetically related birth. Its financing profile differs from treatment of diagnosed infertility because benefit occurs only if stored oocytes are used, survive warming, form embryos, and culminate in live birth.

A recent United States database study identified rapid growth in planned egg freezing—from 4,153 patients in 2014 to 16,436 in 2021—but only 5.7% of those freezing eggs in 2014–2016 returned for warming within five to seven years. Among returners, 78.5% obtained a usable embryo and the cumulative live-birth rate was 28.9% [21]. Follow-up may be too short for younger patients, so eventual use could rise; nevertheless, realised benefit is uncertain when expenditure occurs.

An American Society for Reproductive Medicine guideline found extremely limited evidence for predicting live birth after planned oocyte cryopreservation and insufficient evidence to determine whether lifetime autologous live-birth rates differ from not freezing [22]. Singapore has permitted elective egg freezing for women aged 21–37 since July 2023 while keeping the procedure unsubsidised [23].

The distinction between elective and medically indicated fertility preservation should remain. Fertility preservation before chemotherapy or another fertility-damaging treatment may satisfy a present clinical-necessity test. Planned freezing as a hedge against uncertain future circumstances ordinarily does not. Raising the IVF lifetime withdrawal limit to S$25,000 should therefore not be used as precedent for covering elective egg freezing.

11. Routine PGT-A Is Not Ready for MediSave Financing

PGT-A screens biopsied embryo cells for chromosomal copy-number abnormalities to prioritise embryos for transfer. It may reduce miscarriage or improve selection in particular contexts, but a higher live-birth rate per transfer does not necessarily mean a higher cumulative live-birth rate per retrieval.

In a multicentre randomised trial of 1,212 women aged 20–37 with at least three good-quality blastocysts, cumulative live birth after up to three transfers occurred in 77.2% of the PGT-A group and 81.8% of the conventional-IVF group. Conventional IVF was non-inferior. PGT-A reduced clinical pregnancy loss—8.7% compared with 12.6%—but did not improve cumulative live birth [24].

The American Society for Reproductive Medicine’s 2024 committee opinion describes mixed evidence, stresses the distinction between per-transfer and cumulative outcomes, and does not endorse routine PGT-A for all IVF patients [25]. The United Kingdom Human Fertilisation and Embryology Authority rates PGT-A red for improving the chance of having a baby for most patients, green for reducing miscarriage for most patients, and grey for older women because evidence is insufficient. It warns that incorrect or mosaic classifications can reduce embryo availability [26].

Recent United States class actions have alleged that testing providers overstated PGT-A’s accuracy and utility and that embryos were discarded following test results. The companies have contested the claims; the litigation was ongoing when reported and is not proof of wrongdoing [27]. Its relevance lies in governance: financing should not expand ahead of evidence, consent standards, laboratory quality assurance, and independent assessment.

Singapore should preserve the distinction between PGT-M/PGT-SR, which addresses defined risks of inherited disease or structural rearrangement, and routine PGT-A, which primarily ranks embryos by a screening result. The S$25,000 lifetime withdrawal limit should include only tests already eligible under prevailing clinical-indication rules.

12. Counterarguments and Responses

The governing principle is real-value restoration without scope expansion. A 2004 monetary limit should not remain frozen despite inflation, but updating it does not require more funded cycles, automatic indexation, or coverage of every reproductive technology.

13. Policy Options

14. Recommended Policy Package

14.1 Raise the Lifetime IVF MediSave lifetime withdrawal limit to S$25,000

Government should raise the lifetime lifetime withdrawal limit from S$15,000 to S$25,000 per patient for clinically indicated IVF and currently eligible assisted-conception procedures. The amount closely restores the 2004 lifetime withdrawal limit’s purchasing power under healthcare inflation, with a modest buffer for IVF-specific cost uncertainty. It should be described as a contemporary monetary reset, not a demographic entitlement.

14.2 Adopt a S$10,000/S$8,000/S$7,000 Three-Cycle Schedule

Withdrawals should be limited to S$10,000 for the first complete cycle, S$8,000 for the second, and S$7,000 for the third. Healthcare-inflation translation of the old schedule produces approximately S$9,594/S$7,995/S$6,396; the recommended round values are simple to administer and total S$25,000. A complete cycle must comprise one stimulation and all fresh and frozen transfers from that retrieval.

14.3 Prohibit Further MediSave Withdrawal After Three Complete Cycles

No MediSave withdrawal should be allowed for a fourth or later complete IVF cycle. This boundary protects later-life savings, constrains provider incentives, and recognises that repeated-failure prognosis is highly individual. It does not prohibit further lawful treatment through private payment. Any exceptional public aid should be financed from an explicit appropriation, means-tested, independently reviewed, and reported.

14.4 Retain Exclusions for Elective Egg Freezing and Routine PGT-A

Elective egg freezing should remain outside MediSave because future use and lifetime benefit are uncertain when expenditure occurs. Routine PGT-A should remain excluded unless independent assessment establishes a subgroup with improved cumulative healthy live birth or another patient-important outcome sufficient to justify cost and embryo attrition. Existing support for PGT-M and PGT-SR should continue.

14.5 Require Prognosis Review Before the Second and Third Cycles

The treating centre should document diagnosis, prior stimulation response, oocyte yield, fertilisation, embryo development, transfer history, age, comorbidity, and predicted live-birth probability before later funded cycles. Review should enable shared decision-making and identify futile or unsafe treatment; it should not become a covert socioeconomic exclusion.

14.6 Protect Later-Life Adequacy Through Personalised Disclosure

Before withdrawal, patients should receive a standard statement showing the current MediSave balance, proposed deduction, resulting balance, recent medical claims, and progress toward the Basic Healthcare Sum. Consent materials must make clear that MediSave use draws on the patient’s or spouse’s protected savings and is not a government grant.

14.7 Establish a National ART Outcomes and Financing Registry

Singapore should link cycle-level clinical data with financing and maternal-child outcomes under strict privacy safeguards. Reporting should include initiated and complete cycles, cancellations, cumulative healthy singleton live birth per retrieval, age, diagnosis, embryos transferred, maternal and neonatal outcomes, add-on use, out-of-pocket spending, MediSave drawdown, post-treatment balance, discontinuation, and care after the third cycle.

14.8 Add Targeted Budget Support for Patients With Inadequate Balances

If cost prevents high-prognosis lower-income patients from completing the three-cycle course, government should provide means-tested grants or enhance co-funding. A higher withdrawal lifetime withdrawal limit benefits only patients with sufficient balances. General-revenue support makes redistribution explicit and avoids encouraging vulnerable households to exhaust medical savings.

14.9 Review the Reform After Five Years, Not by Automatic Indexation

The Ministry of Health should publish a baseline and conduct a formal five-year review. It should examine CPI and Health CPI, observed public-centre IVF fees, out-of-pocket costs, use of each cycle allowance, cumulative healthy singleton live births, post-treatment MediSave balances, Basic Healthcare Sum attainment, income distribution, fourth-cycle private continuation, and provider price or add-on responses. Future changes should require an affirmative policy decision.

14.10 Strengthen Non-ART Fertility Policy

ART addresses only part of very-low fertility. Resources should also support timely fertility assessment, prevention and treatment of endometriosis and sexually transmitted infection, maternal-health optimisation, workplace flexibility, affordable childcare, housing certainty, and a more equal distribution of caregiving. These measures affect a broader population and should be evaluated within the same demographic strategy.

15. Implementation and Evaluation Framework

The Ministry of Health should convene a multidisciplinary implementation committee including reproductive specialists, health economists, patient representatives, geriatric-care experts, bioethicists, actuaries, and primary-care physicians. The committee should define a complete cycle, confirm eligible cost components, specify prognosis-review standards, establish the no-withdrawal rule after three cycles, and publish a baseline affordability and account-adequacy report before commencement.

Patients already in treatment should receive clear transitional rules. Clinics should not restructure invoices to maximise withdrawals or divide a complete cycle artificially. Medication, laboratory services, transfers, storage, and add-ons should be itemised, with audits comparing price and service changes before and after implementation.

In February 2026, government confirmed that fertility-health policies, including assisted-conception financing, were under review [28]. A S$25,000 three-cycle lifetime withdrawal limit offers a concrete reform for that review: it updates a 2004 monetary parameter to approximately current purchasing power while preserving the clinical and fiscal boundaries that make MediSave sustainable.

Conclusion

Singapore should no longer treat the S$15,000 IVF MediSave lifetime withdrawal limit as timeless. The S$6,000/S$5,000/S$4,000 structure was set in 2004. By 2025, annual-average All Items prices had risen about 53.5% and Health prices about 59.9%, implying real-value equivalents of approximately S$23,027 and S$23,988. A round S$25,000 lifetime lifetime withdrawal limit is therefore a defensible contemporary reset, especially given uncertainty in translating broad indices into IVF-specific costs.

The reform should restore value without expanding scope. Government should adopt a S$10,000/S$8,000/S$7,000 schedule for three complete cycles and prohibit further MediSave withdrawal thereafter. Some patients can succeed after more attempts, but that fact does not require protected medical savings to finance every positive-probability intervention. The three-cycle rule is an administrable funding boundary grounded in a substantial treatment course, declining and heterogeneous prognosis, later-life savings protection, cost control, and comparative policy practice. It is not a clinical ban; privately financed lawful treatment may continue.

Elective egg freezing and routine PGT-A should remain outside MediSave, while clinically indicated PGT-M and PGT-SR remain eligible. Lower-income patients who cannot benefit from withdrawal permission should receive targeted budget support. Prognosis review, personalised balance disclosure, a national outcomes-and-financing registry, invoice controls, and a five-year evaluation should determine whether the added S$10,000 improves completion and healthy singleton live birth without unacceptable depletion or price inflation.

This position rejects both nominal rigidity and open-ended financing. It recognises infertility as a legitimate medical need, restores the practical value of support within a defined three-cycle course, and preserves MediSave’s life-course purpose. That is a more durable balance of compassion, evidence, equity, and stewardship.

References

1. Singapore Department of Statistics. Births and fertility: latest news and data [Internet]. Singapore: Department of Statistics; 2026. Available from: https://www.singstat.gov.sg/find-data/explore-data-themes/population/births-and-fertility/latest-news-data
2. Ministry of Health Singapore. Marriage and parenthood schemes [Internet]. Singapore: Ministry of Health; 2026. Available from: https://www.moh.gov.sg/managing-expenses/schemes-and-subsidies/marriage-and-parenthood-schemes/
3. Ministry of Health Singapore. Success rate for IVF decreases with more cycles [Internet]. Singapore: Ministry of Health; 2006 Jan 18. Available from: https://www.moh.gov.sg/newsroom/success-rate-for-ivf-decreases-with-more-cycles/
4. Singapore Department of Statistics. Consumer Price Index (CPI), monthly [dataset on the Internet]. Singapore: data.gov.sg; 2026. Available from: https://data.gov.sg/datasets/d_bdaff844e3ef89d39fceb962ff8f0791/view
5. Singapore General Hospital. Regulatory and funding matters [Internet]. Singapore: Singapore General Hospital; 2026. Available from: https://www.sgh.com.sg/our-specialties/centre-for-assisted-reproduction-care/regulatory-and-funding-matters
6. Tan T. Hospitals ramp up IVF capacity as more couples in Singapore seek medical help to have a baby. Straits Times. 2024 May 11. Available from: https://www.sgh.com.sg/news/patient-care/hospitals-ramp-up-ivf-capacity-as-more-couples-in-singapore-seek-medical-help-to-have-a-baby
7. Ministry of Health Singapore. MediSave withdrawal limits for in-vitro fertility treatments [Internet]. Singapore: Ministry of Health; 2023 Sep 19. Available from: https://www.moh.gov.sg/newsroom/medisave-withdrawal-limits-for-in-vitro-fertility-treatments/
8. Central Provident Fund Board. Ordinary Wage lifetime withdrawal limit [dataset on the Internet]. Singapore: data.gov.sg; 2026. Available from: https://data.gov.sg/datasets/d_fcf9b47a2df0c9183875bbfb1c370077/view
9. Central Provident Fund Board. How much CPF contributions to pay [Internet]. Singapore: CPF Board; 2026. Available from: https://www.cpf.gov.sg/employer/employer-obligations/how-much-cpf-contributions-to-pay
10. Central Provident Fund Board. CPF allocation rates from 1 January 2026 [Internet]. Singapore: CPF Board; 2026. Available from: https://www.cpf.gov.sg/content/dam/web/employer/employer-obligations/documents/CPFAllocationRatesfromJanuary2026.pdf
11. Age Well SG. What is Age Well SG? [Internet]. Singapore: Government of Singapore; 2026. Available from: https://www.agewellsg.gov.sg/about/
12. Smith ADAC, Tilling K, Nelson SM, Lawlor DA. Live-birth rate associated with repeat in vitro fertilization treatment cycles. JAMA. 2015;314(24):2654-2662. doi:10.1001/jama.2015.17296.
13. McLernon DJ, Steyerberg EW, te Velde ER, Lee AJ, Bhattacharya S. Predicting the chances of a live birth after one or more complete cycles of in vitro fertilisation: population based study of linked cycle data from 113,873 women. BMJ. 2016;355:i5735. doi:10.1136/bmj.i5735.
14. Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. New England Journal of Medicine. 2009;360(3):236-243. doi:10.1056/NEJMoa0803072.
15. National Institute for Health and Care Excellence. Fertility problems: assessment and treatment. NICE guideline NG257 [Internet]. London: NICE; 2026 [cited 2026 Jul 14]. ISBN: 978-1-4731-9388-8. Available from: https://www.nice.org.uk/guidance/ng257
16. Lazzari E, Gray E, Chambers G. The contribution of assisted reproductive technology to fertility rates and parity transition: an analysis of Australian data. Demographic Research. 2021;45:1081-1096. doi:10.4054/DemRes.2021.45.35.
17. Yun I, Cha W, Nam CM, Nam JY, Park EC. The impact of assisted reproductive technology treatment coverage on marriage, pregnancy, and childbirth in women of childbearing age: an interrupted time-series analysis. BMC Public Health. 2023;23:1379. doi:10.1186/s12889-023-16286-3.
18. Keller E, Botha W, Chambers GM. Does in vitro fertilization treatment provide good value for money? A cost-benefit analysis. Front Glob Womens Health. 2023;4:971553. doi:10.3389/fgwh.2023.971553.
19. Qin J, Liu X, Sheng X, Wang H, Gao S. Assisted reproductive technology and the risk of pregnancy-related complications and adverse pregnancy outcomes in singleton pregnancies: a meta-analysis of cohort studies. Fertility and Sterility. 2016;105(1):73-85.e6. doi:10.1016/j.fertnstert.2015.09.007.
20. American College of Obstetricians and Gynecologists. Perinatal risks associated with assisted reproductive technology. Committee Opinion No. 671. Obstetrics & Gynecology. 2016;128(3):e61-e68. doi:10.1097/AOG.0000000000001643. Available from: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2016/09/perinatal-risks-associated-with-assisted-reproductive-technology
21. Lee MB, Siavoshi M, Kwan L, Kroener L. Elective fertility preservation: a national database study on trends in oocyte cryopreservation and oocyte utilization over a 5- to 7-year follow-up period. American Journal of Obstetrics and Gynecology. 2026;234(2):432-439. doi:10.1016/j.ajog.2025.08.032.
22. Practice Committee of the American Society for Reproductive Medicine. Evidence-based outcomes after oocyte cryopreservation for donor oocyte IVF and planned oocyte cryopreservation: a guideline. Fertility and Sterility. 2021;116(1):36-47. doi:10.1016/j.fertnstert.2021.02.024. Available from: https://www.asrm.org/practice-guidance/practice-committee-documents/evidence-based-outcomes-after-oocyte-cryopreservation-for-donor-oocyte-in-vitro-fertilization-and-planned-oocyte-cryopreservation-a-guideline-2021/
23. Tan T. Elective egg freezing age limit for women in S’pore to go up from 35 to 37 by July. Straits Times. 2023 May 15. Available from: https://www.straitstimes.com/singapore/from-july-age-limit-for-women-to-opt-for-elective-egg-freezing-donation-will-be-raised-from-35-to-37
24. Yan J, Qin Y, Zhao H, Sun Y, Gong F, Li R, Sun X, Ling X, Li H, Hao C, Tan J, Yang J, Zhu Y, Liu F, Chen D, Wei D, Lu J, Ni T, Zhou W, Wu K, Gao Y, Shi Y, Lu Y, Zhang T, Wu W, Ma X, Ma H, Fu J, Zhang J, Meng Q, Zhang H, Legro RS, Chen ZJ. Live birth with or without preimplantation genetic testing for aneuploidy. New England Journal of Medicine. 2021;385(22):2047-2058. doi:10.1056/NEJMoa2103613.
25. Practice Committee of the American Society for Reproductive Medicine. The use of preimplantation genetic testing for aneuploidy: a committee opinion. Fertility and Sterility. 2024;122(3):421-434. doi:10.1016/j.fertnstert.2024.04.013. Available from: https://www.asrm.org/practice-guidance/practice-committee-documents/the-use-of-preimplantation-genetic-testing-for-aneuploidy-a-committee-opinion-2024/
26. Human Fertilisation and Embryology Authority. Pre-implantation genetic testing for aneuploidy (PGT-A). London: HFEA. Available from: https://www.hfea.gov.uk/treatments/treatment-add-ons/pre-implantation-genetic-testing-for-aneuploidy-pgt-a/
27. Ducharme J. IVF patients say a test caused them to discard embryos. Now they’re suing. Time. 2025 Mar 6. Available from: https://time.com/7264271/ivf-pgta-test-lawsuit/
28. Ministry of Health Singapore. Enhanced funding or subsidies for elective egg freezing, IVF and other fertility treatments for older couples: oral answer to parliamentary question. Singapore: Government of Singapore; 2026 Feb 26. Available from: https://telescope.gov.sg/transcript/28191